Noted: But no minutes had been kept of the meeting, which was supposed to be anonymous. (See “More Questions On Vytorin Panel”). An attempt to create an account of what happened there began later on. But one panelist, James Stein, a cardiac imaging expert at the University of Wisconsin, disagreed with assertions made in the document.
“This really overstates our recommendation,” Stein wrote to Schering-Plough executive John Strony. “It was the decision of the company to change the primary endpoint.”